Frontier Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-53,277
| Closed | -$2.88M | – | 289 |
|
|
2024
Q2 | $2.88M | Sell |
53,277
-48,821
| -48% | -$2.64M | 0.03% | 263 |
|
|
2024
Q1 | $6.96M | Sell |
102,098
-152,874
| -60% | -$10.4M | 0.07% | 234 |
|
|
2023
Q4 | $16M | Sell |
254,972
-10,163
| -4% | -$636K | 0.16% | 176 |
|
|
2023
Q3 | $12M | Sell |
265,135
-110,653
| -29% | -$5.02M | 0.13% | 180 |
|
|
2023
Q2 | $21.1M | Buy |
375,788
+329,441
| +711% | +$18.5M | 0.2% | 152 |
|
|
2023
Q1 | $2.1M | Sell |
46,347
-9,524
| -17% | -$431K | 0.02% | 249 |
|
|
2022
Q4 | $2.27M | Sell |
55,871
-263,039
| -82% | -$10.7M | 0.02% | 249 |
|
|
2022
Q3 | $20.8M | Buy |
318,910
+150,425
| +89% | +$9.83M | 0.24% | 143 |
|
|
2022
Q2 | $10.2M | Buy |
168,485
+20,568
| +14% | +$1.25M | 0.12% | 204 |
|
|
2022
Q1 | $9.29M | Buy |
+147,917
| New | +$9.29M | 0.08% | 217 |
|
|
2021
Q1 | – | Sell |
-3,186
| Closed | -$488K | – | 282 |
|
|
2020
Q4 | $488K | Sell |
3,186
-1
| -0% | -$153 | ﹤0.01% | 282 |
|
|
2020
Q3 | $267K | Sell |
3,187
-156,271
| -98% | -$13.1M | ﹤0.01% | 290 |
|
|
2020
Q2 | $11.7M | Buy |
159,458
+44,346
| +39% | +$3.26M | 0.1% | 202 |
|
|
2020
Q1 | $4.88M | Buy |
115,112
+38,476
| +50% | +$1.63M | 0.05% | 236 |
|
|
2019
Q4 | $4.67M | Buy |
+76,636
| New | +$4.67M | 0.03% | 253 |
|
|
2018
Q3 | – | Sell |
-54,631
| Closed | -$3.21M | – | 292 |
|
|
2018
Q2 | $3.21M | Buy |
+54,631
| New | +$3.21M | 0.02% | 278 |
|